Sutro Biopharma (STRO) Q2 2026 earnings — TrendMatrix coverage
MISS · WIDER LOSS-1.9% vs estimateEPS -$2.31 vs -$2.27 estVerdict Sell → Hold
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
Key numbers
- Adjusted EPS
- -$2.31
- Estimate
- -$2.27
- Surprise
- -1.9%
- Revenue (period 2026-06-30)
- $9.8M
- Score at report (before → after)
- 4.6 → 4.7/10
Revenue source: xbrl.
Report record · Q2 2026
How the report landed
Sutro Biopharma (STRO) reported a wider loss than forecast — adjusted EPS of -$2.31 against the -$2.27 estimate (a 1.9% shortfall). TrendMatrix's engine moved from Sell (4.6/10) to Hold at 4.7/10 after the report — the engine's score rose despite the miss.
Around the report
Coverage in the report window
- Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34 — benzinga, 2026-08-13
- Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target — benzinga, 2026-08-13
- Why is Sutro Biopharma Stock Falling On Wednesday? — benzinga, 2026-08-12